Fosun Kite Receives NMPA Approval for Clinical Trial of Axicabtagene Ciloleucel Injection in Relapsed/Refractory Large B-Cell Lymphoma

Gelonghui, August 25th :: Fosun Pharmaceutical announced that Fosun Kite Biotechnology Co., Ltd., in which the company has invested, has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for Axicabtagene Ciloleucel Injection (trade name: Yikaida®) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) who are ineffective with first-line immunochemotherapy or relapse within 12 months after first-line immunochemotherapy.